Daiichi Sankyo and Alteogen Collaborate on Subcutaneous Enhertu Development in $300M Licensing Agreement

Partnership:
Daiichi Sankyo has entered into a $300 million licensing agreement with Korea's Alteogen to develop a subcutaneous (SC) formulation of Enhertu using Alteogen's human hyaluronidase, ALT-B4[1][5].

Financial Terms:
Daiichi Sankyo will pay Alteogen $20 million upfront as part of the deal, with potential future payments totaling $300 million[1][5].

Development Focus:
The collaboration aims to create a subcutaneous version of Enhertu, a cancer treatment, which could offer a more convenient administration method compared to intravenous formulations[1][5].

Technology:
Alteogen's human hyaluronidase, ALT-B4, is key to the development of the subcutaneous Enhertu formulation, enabling the drug to be administered under the skin[1][5].

Impact:
This partnership could expand the accessibility and ease of use of Enhertu, potentially benefiting patients with certain types of cancer[1][5].